Baidu
map

打给孩子的65万支不合格疫苗,国家药监局通报全新情况

2018-07-23 佚名 网络综合

长生生物疫苗造假事件持续发酵,引爆公众对疫苗安全问题的关注,恐慌、愤怒情绪不断蔓延。今日,国家药监局负责人也通报了长春长生生物科技有限责任公司违法违规生产冻干人用狂犬病疫苗案件有关情况。业内人士表示,问题疫苗,对人体的安全没有影响,最大的风险在于可能失效,导致无法预防对应的疾病。疫苗之殇,诚然愤怒极致,但希望家长不能因噎废食,若因害怕放弃疫苗接种,风险最大的还是孩子。

7月22日,李克强总理就疫苗事件作出批示:此次疫苗事件突破人的道德底线,必须给全国人民一个明明白白的交代。

李克强在批示中要求,国务院要立刻派出调查组,对所有疫苗生产、销售等全流程全链条进行彻查,尽快查清事实真相,不论涉及到哪些企业、哪些人都坚决严惩不贷、绝不姑息。对一切危害人民生命安全的违法犯罪行为坚决重拳打击,对不法分子坚决依法严惩,对监管失职渎职行为坚决严厉问责。尽早还人民群众一个安全、放心、可信任的生活环境。

疫苗事情始末

7月15日,国家药品监督管理局发布通告:国家药监局根据线索组织检查组对长春长生生物科技有限责任公司(以下简称“长春长生”)生产现场进行飞行检查。检查组发现,长春长生在冻干人用狂犬病疫苗生产过程中存在记录造假等严重违反《药品生产质量管理规范》(药品GMP)行为。根据检查结果,国家药监局迅速责成吉林省食品药品监督管理局收回长春长生相关《药品GMP证书》。通告称,所有涉事批次产品尚未出厂和上市销售。

7月16日,长生生物发布公告,表示正对有效期内所有批次的冻干人用狂犬病疫苗全部实施召回。

7月17日,长春长生发声明称,此次所有涉事疫苗尚未出厂销售,所有已经上市的人用狂犬病疫苗产品质量符合国家注册标准。然而,长春长生单方面的质量保证并不能给公众信心,尤其是近几年使用过其疫苗的人们,担忧情绪日渐积累。

7月18日,山东疾控中心发布信息,宣布山东省已全面停用长春长生生物科技有限责任公司生产的人用狂犬病疫苗。

此时,事件的发展似乎仍在可控范围。但仅仅两天后,舆论彻底失控。

7月20日,吉林省食药监局的一纸行政处罚公示,彻底将公众的早已郁积多日的愤怒情绪引爆:长春长生生产的“吸附无细胞白百破联合疫苗”(批号:201605014-01)经中国食品药品检定研究院检验,检验结果【效价测定】项不符合规定,按劣药论处。这条处罚信息,针对的是2017年11月的一起违法事件。由长春长生生物科技有限公司和武汉生物制品研究所有限责任公司生产的各一批次共计65万余支百白破疫苗效价指标不符合标准规定,食药监总局已责令企业查明流向,并要求立即停止使用不合格产品。

有问题的疫苗流向何处

经检查,长春长生生物科技有限公司生产的批号为201605014-01的疫苗共计252600支,全部销往山东省疾病预防控制中心;

武汉生物制品研究所有限责任公司生产的批号为201607050-2的疫苗共计400520支,销往重庆市疾病预防控制中心190520支,销往河北省疾病预防控制中心210000支。

国家药监局负责人通报最新情况

据央视新闻最新报道,国家药监局负责人7月22日通报了长春长生生物科技有限责任公司违法违规生产冻干人用狂犬病疫苗案件有关情况。

根据举报提供的线索,7月5日,国家药监局会同吉林省局对长春长生公司进行飞行检查;7月15日,国家药监局会同吉林省局组成调查组进驻企业全面开展调查。7月15日,国家药监局发布了《关于长春长生生物科技有限责任公司违法违规生产冻干人用狂犬病疫苗的通告》。



现已查明,企业编造生产记录和产品检验记录,随意变更工艺参数和设备。上述行为严重违反了《中华人民共和国药品管理法》《药品生产质量管理规范》有关规定,国家药监局已责令企业停止生产,收回药品GMP证书,召回尚未使用的狂犬病疫苗。国家药监局会同吉林省局已对企业立案调查,涉嫌犯罪的移送公安机关追究刑事责任。

按照疫苗管理有关规定,所有企业上市销售的疫苗,均需报请中国食品药品检定研究院批签发,批签发过程中要对所有批次疫苗安全性进行检验,对一定比例批次疫苗有效性进行检验。该企业已上市销售使用疫苗均经过法定检验,未发现质量问题。为进一步确认已上市疫苗的有效性,已启动对企业留样产品抽样进行实验室评估。

另据中国疾病预防控制中心监测,我国的狂犬病发病率近年来逐步下降。

药监局已部署全国疫苗生产企业进行自查,确保企业按批准的工艺组织生产,严格遵守GMP生产规范,所有生产检验过程数据要真实、完整、可靠,可以追溯。国家药监局将组织对所有疫苗生产企业进行飞行检查,对违反法律法规规定的行为要严肃查处。

负责人说,该企业是一年内被第二次发现产品生产质量问题。去年10月,原食药监总局抽样检验中发现该企业生产的1批次百白破疫苗效价不合格,该产品目前仍在停产中,有关补种工作原国家卫计委会同原食药监总局已于今年2月进行了部署。

规范行业发展,保住公众对疫苗的信任

正如今日人民日报发布的评论文章所言,无论是生产企业还是监管部门,都必须以“敬畏生命”,以更严格的生产标准、更严厉的监管常态、更严重的违法处罚规范行业发展,保住公众对疫苗的信任。

接种过疫苗的家长们当务之急,先查询儿童是否接种了不合格的百白破疫苗。儿童家长或监护人可以查看儿童预防接种证上的百白破疫苗接种记录,与公布的疫苗生产企业和批号进行对照,判断是否接种了相应批号的不合格百白破疫苗。也可以咨询接种单位,由接种单位协助查询所接种百白破疫苗的批号,判断是否接种了相应批号的不合格百白破疫苗。还可以拨打12320卫生热线咨询。

如果妈妈们发现自己孩子已接种不合格百白破疫苗,考虑到尚未得到官方的应对之策,对于是否补种等问题建议等待官方的进一步消息。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1668961, encodeId=48b91668961ef, content=<a href='/topic/show?id=1086203266c' target=_blank style='color:#2F92EE;'>#不合格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20326, encryptionId=1086203266c, topicName=不合格)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f77c26479803, createdName=echonoir, createdTime=Thu Oct 04 19:49:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345786, encodeId=0c14345e86e9, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Sep 20 08:41:32 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343740, encodeId=48c7343e40af, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sat Sep 08 16:34:13 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339150, encodeId=a3cd33915002, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Aug 17 16:52:23 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336807, encodeId=b23333680eb1, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon Aug 06 09:15:43 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336664, encodeId=6d2733666468, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Aug 05 18:59:05 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335949, encodeId=3dcd3359490e, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Aug 03 07:34:31 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301594, encodeId=293f130159435, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Jul 25 00:49:00 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429162, encodeId=1bbf1429162ca, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Wed Jul 25 00:49:00 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333571, encodeId=19d93335e103, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Mon Jul 23 11:26:31 CST 2018, time=2018-07-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1668961, encodeId=48b91668961ef, content=<a href='/topic/show?id=1086203266c' target=_blank style='color:#2F92EE;'>#不合格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20326, encryptionId=1086203266c, topicName=不合格)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f77c26479803, createdName=echonoir, createdTime=Thu Oct 04 19:49:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345786, encodeId=0c14345e86e9, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Sep 20 08:41:32 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343740, encodeId=48c7343e40af, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sat Sep 08 16:34:13 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339150, encodeId=a3cd33915002, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Aug 17 16:52:23 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336807, encodeId=b23333680eb1, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon Aug 06 09:15:43 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336664, encodeId=6d2733666468, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Aug 05 18:59:05 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335949, encodeId=3dcd3359490e, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Aug 03 07:34:31 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301594, encodeId=293f130159435, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Jul 25 00:49:00 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429162, encodeId=1bbf1429162ca, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Wed Jul 25 00:49:00 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333571, encodeId=19d93335e103, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Mon Jul 23 11:26:31 CST 2018, time=2018-07-23, status=1, ipAttribution=)]
    2018-09-20 大爰

    学习了谢谢分享!!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1668961, encodeId=48b91668961ef, content=<a href='/topic/show?id=1086203266c' target=_blank style='color:#2F92EE;'>#不合格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20326, encryptionId=1086203266c, topicName=不合格)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f77c26479803, createdName=echonoir, createdTime=Thu Oct 04 19:49:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345786, encodeId=0c14345e86e9, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Sep 20 08:41:32 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343740, encodeId=48c7343e40af, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sat Sep 08 16:34:13 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339150, encodeId=a3cd33915002, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Aug 17 16:52:23 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336807, encodeId=b23333680eb1, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon Aug 06 09:15:43 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336664, encodeId=6d2733666468, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Aug 05 18:59:05 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335949, encodeId=3dcd3359490e, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Aug 03 07:34:31 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301594, encodeId=293f130159435, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Jul 25 00:49:00 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429162, encodeId=1bbf1429162ca, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Wed Jul 25 00:49:00 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333571, encodeId=19d93335e103, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Mon Jul 23 11:26:31 CST 2018, time=2018-07-23, status=1, ipAttribution=)]
    2018-09-08 大爰

    学习了谢谢分享!!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1668961, encodeId=48b91668961ef, content=<a href='/topic/show?id=1086203266c' target=_blank style='color:#2F92EE;'>#不合格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20326, encryptionId=1086203266c, topicName=不合格)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f77c26479803, createdName=echonoir, createdTime=Thu Oct 04 19:49:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345786, encodeId=0c14345e86e9, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Sep 20 08:41:32 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343740, encodeId=48c7343e40af, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sat Sep 08 16:34:13 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339150, encodeId=a3cd33915002, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Aug 17 16:52:23 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336807, encodeId=b23333680eb1, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon Aug 06 09:15:43 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336664, encodeId=6d2733666468, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Aug 05 18:59:05 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335949, encodeId=3dcd3359490e, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Aug 03 07:34:31 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301594, encodeId=293f130159435, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Jul 25 00:49:00 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429162, encodeId=1bbf1429162ca, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Wed Jul 25 00:49:00 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333571, encodeId=19d93335e103, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Mon Jul 23 11:26:31 CST 2018, time=2018-07-23, status=1, ipAttribution=)]
    2018-08-17 大爰

    学习了谢谢分享!!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1668961, encodeId=48b91668961ef, content=<a href='/topic/show?id=1086203266c' target=_blank style='color:#2F92EE;'>#不合格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20326, encryptionId=1086203266c, topicName=不合格)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f77c26479803, createdName=echonoir, createdTime=Thu Oct 04 19:49:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345786, encodeId=0c14345e86e9, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Sep 20 08:41:32 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343740, encodeId=48c7343e40af, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sat Sep 08 16:34:13 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339150, encodeId=a3cd33915002, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Aug 17 16:52:23 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336807, encodeId=b23333680eb1, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon Aug 06 09:15:43 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336664, encodeId=6d2733666468, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Aug 05 18:59:05 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335949, encodeId=3dcd3359490e, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Aug 03 07:34:31 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301594, encodeId=293f130159435, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Jul 25 00:49:00 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429162, encodeId=1bbf1429162ca, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Wed Jul 25 00:49:00 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333571, encodeId=19d93335e103, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Mon Jul 23 11:26:31 CST 2018, time=2018-07-23, status=1, ipAttribution=)]
    2018-08-06 大爰

    学习了谢谢分享!!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1668961, encodeId=48b91668961ef, content=<a href='/topic/show?id=1086203266c' target=_blank style='color:#2F92EE;'>#不合格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20326, encryptionId=1086203266c, topicName=不合格)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f77c26479803, createdName=echonoir, createdTime=Thu Oct 04 19:49:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345786, encodeId=0c14345e86e9, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Sep 20 08:41:32 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343740, encodeId=48c7343e40af, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sat Sep 08 16:34:13 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339150, encodeId=a3cd33915002, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Aug 17 16:52:23 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336807, encodeId=b23333680eb1, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon Aug 06 09:15:43 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336664, encodeId=6d2733666468, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Aug 05 18:59:05 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335949, encodeId=3dcd3359490e, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Aug 03 07:34:31 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301594, encodeId=293f130159435, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Jul 25 00:49:00 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429162, encodeId=1bbf1429162ca, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Wed Jul 25 00:49:00 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333571, encodeId=19d93335e103, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Mon Jul 23 11:26:31 CST 2018, time=2018-07-23, status=1, ipAttribution=)]
    2018-08-05 大爰

    学习并分享!!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1668961, encodeId=48b91668961ef, content=<a href='/topic/show?id=1086203266c' target=_blank style='color:#2F92EE;'>#不合格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20326, encryptionId=1086203266c, topicName=不合格)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f77c26479803, createdName=echonoir, createdTime=Thu Oct 04 19:49:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345786, encodeId=0c14345e86e9, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Sep 20 08:41:32 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343740, encodeId=48c7343e40af, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sat Sep 08 16:34:13 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339150, encodeId=a3cd33915002, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Aug 17 16:52:23 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336807, encodeId=b23333680eb1, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon Aug 06 09:15:43 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336664, encodeId=6d2733666468, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Aug 05 18:59:05 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335949, encodeId=3dcd3359490e, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Aug 03 07:34:31 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301594, encodeId=293f130159435, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Jul 25 00:49:00 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429162, encodeId=1bbf1429162ca, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Wed Jul 25 00:49:00 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333571, encodeId=19d93335e103, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Mon Jul 23 11:26:31 CST 2018, time=2018-07-23, status=1, ipAttribution=)]
    2018-08-03 大爰

    学习并分享!!

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1668961, encodeId=48b91668961ef, content=<a href='/topic/show?id=1086203266c' target=_blank style='color:#2F92EE;'>#不合格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20326, encryptionId=1086203266c, topicName=不合格)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f77c26479803, createdName=echonoir, createdTime=Thu Oct 04 19:49:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345786, encodeId=0c14345e86e9, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Sep 20 08:41:32 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343740, encodeId=48c7343e40af, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sat Sep 08 16:34:13 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339150, encodeId=a3cd33915002, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Aug 17 16:52:23 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336807, encodeId=b23333680eb1, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon Aug 06 09:15:43 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336664, encodeId=6d2733666468, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Aug 05 18:59:05 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335949, encodeId=3dcd3359490e, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Aug 03 07:34:31 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301594, encodeId=293f130159435, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Jul 25 00:49:00 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429162, encodeId=1bbf1429162ca, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Wed Jul 25 00:49:00 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333571, encodeId=19d93335e103, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Mon Jul 23 11:26:31 CST 2018, time=2018-07-23, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1668961, encodeId=48b91668961ef, content=<a href='/topic/show?id=1086203266c' target=_blank style='color:#2F92EE;'>#不合格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20326, encryptionId=1086203266c, topicName=不合格)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f77c26479803, createdName=echonoir, createdTime=Thu Oct 04 19:49:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345786, encodeId=0c14345e86e9, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Sep 20 08:41:32 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343740, encodeId=48c7343e40af, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sat Sep 08 16:34:13 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339150, encodeId=a3cd33915002, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Aug 17 16:52:23 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336807, encodeId=b23333680eb1, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon Aug 06 09:15:43 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336664, encodeId=6d2733666468, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Aug 05 18:59:05 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335949, encodeId=3dcd3359490e, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Aug 03 07:34:31 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301594, encodeId=293f130159435, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Jul 25 00:49:00 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429162, encodeId=1bbf1429162ca, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Wed Jul 25 00:49:00 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333571, encodeId=19d93335e103, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Mon Jul 23 11:26:31 CST 2018, time=2018-07-23, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1668961, encodeId=48b91668961ef, content=<a href='/topic/show?id=1086203266c' target=_blank style='color:#2F92EE;'>#不合格#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20326, encryptionId=1086203266c, topicName=不合格)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f77c26479803, createdName=echonoir, createdTime=Thu Oct 04 19:49:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345786, encodeId=0c14345e86e9, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Thu Sep 20 08:41:32 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=343740, encodeId=48c7343e40af, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sat Sep 08 16:34:13 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339150, encodeId=a3cd33915002, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Aug 17 16:52:23 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336807, encodeId=b23333680eb1, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Mon Aug 06 09:15:43 CST 2018, time=2018-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336664, encodeId=6d2733666468, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sun Aug 05 18:59:05 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=335949, encodeId=3dcd3359490e, content=学习并分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Aug 03 07:34:31 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301594, encodeId=293f130159435, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Jul 25 00:49:00 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429162, encodeId=1bbf1429162ca, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Wed Jul 25 00:49:00 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=333571, encodeId=19d93335e103, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Mon Jul 23 11:26:31 CST 2018, time=2018-07-23, status=1, ipAttribution=)]
    2018-07-23 sunfeifeiyang

    0

相关资讯

癌症治疗性疫苗及相关生物制品临床试验基本规范(上)

一、前言 本文摘译自2007年1月份刊出的英文综述A Clinical Development Paradigm For Cancer Vaccines and Related Biologics(J Immunother. volume 30,number 1, January 2007)。本篇内容节译自该文的起草背景和摘要部分。 2004年12月至2005年12月期间,

Sci Transl Med:HIV疫苗研究的曙光

虽然对HIV疫苗的研究已经进行了几十年,但是科学家们还未能开发出一种能够有效预防感染的HIV疫苗。

Clin Infect Dis:13价肺炎球菌结合疫苗对老年人肺炎球菌负荷的影响 了解一下!

肺炎球菌结合疫苗对成年肺炎球菌和其他细菌鼻咽部负载患病率的影响未知。2018年6月,发表在《Clin Infect Dis》的一项研究调查了13价肺炎球菌结合疫苗(PCV13)对肺炎球菌负载的影响。

美国的疫苗安全是如何监管的?

导言最近寨卡病毒感染病例已经在包括美国在内的全球30余个国家被诊断,昨天(2月1日),在美国被证实寨卡病毒可以通过性传播,这更增加了该病毒的危险性。寨卡病毒被怀疑是新生儿小头症的罪魁祸首,所以世界卫生组织近日宣布寨卡病毒为紧急公共卫生事件,这也是继埃博拉病毒之后的又一全球性公共卫生危机。每当这个时候,媒体就会拷问相关疫苗的研发进展。而预防性疫苗由于是用于健康人群,所以对疫苗的安全性和一般药品相

单纯抗HBc阳性,要紧吗?要打疫苗吗?

门诊常遇持“二对半”化验单的咨询者。所谓“二对半”,为乙肝血清标志物检查,包括二个抗原,三个抗体,因HBc抗原一般实验室难以检测,只查抗体,称为“二对半”。抗HBc阳性,即为最后一项标志物阳性。

疫苗引爆脊髓灰质炎 威胁全球根除工作

罕见的情况下,脊髓灰质炎疫苗中被削弱的病毒可以恢复毒性,引发疫情。 在刚果民主共和国埃博拉疫情的阴影下,另一种可怕的病毒正在蔓延:脊髓灰质炎。公共卫生专家几个月来一直在努力消灭这种病毒,但它仍在传播。目前,它已经使该国29名儿童瘫痪,6月21日,有报道称在与乌干达接壤的边界上,出现了一例病例,这加剧了人们对该病毒将横扫非洲的担忧。

Baidu
map
Baidu
map
Baidu
map